title: The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM).
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Diels
authors.affiliation: Janssen-Cilag Germany, Mainz, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Angermund
authors.affiliation: Janssen-Cilag UK, High Wycombe, UK.
authors.forename: M
authors.initials: M
authors.lastname: Schroeder
authors.affiliation: Janssen-Cilag UK, High Wycombe, UK.
authors.forename: M
authors.initials: M
authors.lastname: Worbes-Cerezo
authors.affiliation: Janssen-Cilag UK, High Wycombe, UK.
authors.forename: G
authors.initials: G
authors.lastname: Thompson